Posted by Michael Wonder on 26 Jul 2021
Rhythm Pharmaceuticals announces European Commission authorisation of Imcivree (setmelanotide) for the treatment of obesity and control of hunger associated with POMC, PCSK1 and LEPR deficiency
23 July 2021 - First ever authorised treatment option in the European Union for these rare genetic diseases of obesity.
Rhythm Pharmaceuticals today announced that the European Commission has granted marketing authorisation to Imcivree (setmelanotide) in the European Union for the treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin, including proprotein convertase subtilisin/kexin type 1, deficiency or biallelic leptin receptor deficiency in adults and children 6 years of age and above.
